Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–37 of 13 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 2Phase 3 Interventional Results available

Arimoclomol in Sporadic Inclusion Body Myositis

NCT00769860
Conditions
Inclusion Body Myositis
Interventions
Arimoclomol, Placebo
Drug · Other
Lead sponsor
Richard Barohn, MD
Other
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Sporadic Inclusion Body Myositis (sIBM)
Interventions
BYM338 (Bimagrumab)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Phoenix, Arizona • Boston, Massachusetts
Conditions
Myositis, Inclusion Body
Interventions
Alemtuzumab (Campath)
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
25 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Completed No phase listed Observational Accepts healthy volunteers

Study and Treatment of Inflammatory Muscle Diseases

NCT00001265
Conditions
Dermatomyositis, Polymyositis
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
16 Years and older
Enrollment
1,325 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1992 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Neuromuscular Diseases (NMD), Amyotrophic Lateral Sclerosis, Myasthenia Gravis, Lambert-eaton Myasthenic Syndrome, Primary Lateral Sclerosis, Spinal Muscular Atrophy, Charcot Marie Tooth Disease (CMT), Fascioscapulohumeral Muscular Dystrophy, Inclusion Body Myositis, Mitochondrial Myopathy, Nemaline Myopathy, Centronuclear Myopathy, Postpolio Syndrome, Pompe Disease (Late-onset), Chronic Inflammatory Demyelinating Polyneuropathy, Hereditary Spastic Paraplegia, Postural Orthostatic Tachycardia Syndrome (POTS), Progressive Muscular Atrophy
Interventions
Whole-body Electrical Muscle Stimulation Exercise
Device
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Columbia, Missouri
Conditions
Inclusion Body Myositis (IBM)
Interventions
Natalizumab
Drug
Lead sponsor
Phoenix Neurological Associates, LTD
Other
Eligibility
21 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Polymyositis, Dermatomyositis
Interventions
BAF312, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Inclusion Body Myositis, Sporadic Inclusion Body Myositis
Interventions
Phenylbutyrate Oral Tablet
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Kansas City, Kansas
Completed Phase 2 Interventional Results available

Study of Arimoclomol in Inclusion Body Myositis (IBM)

NCT02753530
Conditions
Inclusion Body Myositis
Interventions
Arimoclomol, Placebo
Drug · Other
Lead sponsor
ZevraDenmark
Industry
Eligibility
45 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
11
States / cities
Phoenix, Arizona • Irvine, California • Aurora, Colorado + 8 more
Conditions
Inclusion Body Myositis
Interventions
PAMSys pendant PAMSys wrist sensors
Device
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
45 Years and older
Enrollment
20 participants
Timeline
2023 – 2028
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Dermatomyositis, Inclusion Body Myositis, Polymyositis
Interventions
Gamma Globulin
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1990 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Healthy
Interventions
CaHMB, HMB Free Acid Gel, Placebo, Placebo Gel Dosage
Dietary Supplement
Lead sponsor
Metabolic Technologies Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Ames, Iowa
Conditions
Overweight and Obesity, Inflammation; Muscle, Sedentary Lifestyle
Interventions
Diet-Induced Weight Loss, Aerobic Exercise Training
Behavioral
Lead sponsor
Miami University
Other
Eligibility
58 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Oxford, Ohio